These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6222235)

  • 1. [High-dose gestagen therapy with medroxyprogesterone acetate in metastasizing breast carcinoma].
    Bastert G; Michel RT
    Med Welt; 1983 Mar; 34(12):378-82. PubMed ID: 6222235
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
    Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract]   [Full Text] [Related]  

  • 3. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High-dose gestagen therapy in breast cancer].
    Beaufort F; Fereberger W
    Wien Med Wochenschr; 1983 Apr; 133(7):169-73. PubMed ID: 6223450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T; Izuo M; Nomura Y; Kubo K; Abe O; Enomoto K; Takatani O
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1994-2004. PubMed ID: 6223590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
    Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W
    Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
    Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
    Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effects of medroxyprogesterone acetate in recurrent or advanced breast cancer].
    Yoshida M; Murai H; Miura S
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):516-23. PubMed ID: 3159345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer].
    Dryzhak VI
    Vopr Onkol; 1989; 35(7):771-8. PubMed ID: 2528239
    [No Abstract]   [Full Text] [Related]  

  • 12. [High-dosage oral gestagen therapy as a failure-regime in metastatic breast cancer].
    Jonat W; Knapp W; Schumann B; Trapp H; Vanhecke C; Maass H
    Dtsch Med Wochenschr; 1984 Jan; 109(2):46-9. PubMed ID: 6692762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hormonal control of disseminated breast cancer].
    Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
    Sov Med; 1990; (6):94-7. PubMed ID: 2144368
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II evaluation of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group Study.
    Tan YO; Hendrickson C; McWhirter K; Kohler M; Hannigan JF; Carlson RW
    Cancer Treat Rep; 1987 Oct; 71(10):969-70. PubMed ID: 2958131
    [No Abstract]   [Full Text] [Related]  

  • 15. [Gestagen therapy of breast cancer. Effect of high doses on the blood coagulation system].
    Schenk H; Fereberger W
    MMW Munch Med Wochenschr; 1983 Oct; 125(40):875-6. PubMed ID: 6226871
    [No Abstract]   [Full Text] [Related]  

  • 16. [Endocrine treatment of metastasizing breast cancer in menopausal women. A randomized comparison between tamoxifen (Nolvadex) versus tamoxifen and medroxyprogesterone acetate (Clinovir)].
    Mouridsen HT; Ellemann K; Mattsson W; Palshof T; Daehnfeldt J; Rose C
    Ugeskr Laeger; 1979 Jul; 141(31):2113-6. PubMed ID: 483409
    [No Abstract]   [Full Text] [Related]  

  • 17. [High-dosed gestagen therapy of the metastatic mammary carcinoma (author's transl)].
    Firusian N; Becher R
    Strahlentherapie; 1981 Dec; 157(12):808-12. PubMed ID: 7330909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose oral medroxyprogesterone acetate in heavily pretreated patients with metastatic breast cancer.
    Goss PE; Ashley S; Powles TJ; Coombes RC
    Cancer Treat Rep; 1986 Jun; 70(6):777-9. PubMed ID: 2942246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer.
    Iino Y; Takeo T; Sugamata N; Aoyagi H; Takai Y; Takei H; Ando T; Koibuchi Y; Yokoe T; Ohwada S
    Anticancer Res; 1995; 15(3):1061-4. PubMed ID: 7645926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.